These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 30267321)
1. Lanadelumab: First Global Approval. Syed YY Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321 [TBL] [Abstract][Full Text] [Related]
2. Lanadelumab: A Review in Hereditary Angioedema. Syed YY Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114 [TBL] [Abstract][Full Text] [Related]
3. Lanadelumab to treat hereditary angioedema. Wedi B Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612 [TBL] [Abstract][Full Text] [Related]
4. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362 [TBL] [Abstract][Full Text] [Related]
5. Lanadelumab for the prevention of attacks in hereditary angioedema. Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602 [No Abstract] [Full Text] [Related]
6. A review of kallikrein inhibitor lanadelumab in hereditary angioedema. Hwang G; Johri A; Ng S; Craig T Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673 [TBL] [Abstract][Full Text] [Related]
7. Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. Busse P; Kaplan A J Allergy Clin Immunol Pract; 2022 Mar; 10(3):716-722. PubMed ID: 34838707 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema. Wang Y; Marier JF; Kassir N; Chang C; Martin P Clin Transl Sci; 2020 Nov; 13(6):1208-1216. PubMed ID: 32407574 [TBL] [Abstract][Full Text] [Related]
9. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy. Bova M; Valerieva A; Wu MA; Senter R; Perego F Drug Des Devel Ther; 2019; 13():3635-3646. PubMed ID: 31695331 [TBL] [Abstract][Full Text] [Related]
10. Lanadelumab for the treatment of hereditary angioedema. Wu MA Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963 [No Abstract] [Full Text] [Related]
11. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses. Mendivil J; Malmenäs M; Haeussler K; Hunger M; Jain G; Devercelli G Drugs R D; 2021 Mar; 21(1):113-121. PubMed ID: 33646565 [TBL] [Abstract][Full Text] [Related]
12. Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience. Hahn J; Trainotti S; Wigand MC; Schuler PJ; Hoffmann TK; Greve J J Drugs Dermatol; 2020 Oct; 19(10):978-983. PubMed ID: 33026762 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study. Hide M; Ohsawa I; Nurse C; Yu M; J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953 [TBL] [Abstract][Full Text] [Related]
14. Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five cases. Hioki C; Oda Y; Moriwaki S; Fukunaga A J Dermatol; 2024 Jun; 51(6):873-877. PubMed ID: 38268496 [TBL] [Abstract][Full Text] [Related]
15. Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study. Magerl M; Schiffhorst G; Fanter L; Müller G; Hirche C; Berkemeier F; Aygören E Allergy; 2024 Jan; 79(1):215-224. PubMed ID: 37641968 [TBL] [Abstract][Full Text] [Related]
16. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674 [TBL] [Abstract][Full Text] [Related]
17. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Riedl MA; Maurer M; Bernstein JA; Banerji A; Longhurst HJ; Li HH; Lu P; Hao J; Juethner S; Lumry WR; Allergy; 2020 Nov; 75(11):2879-2887. PubMed ID: 32452549 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic monoclonal antibodies with a focus on hereditary angioedema. Zuraw BL; Maurer M; Sexton DJ; Cicardi M Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344 [TBL] [Abstract][Full Text] [Related]
19. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema. Stolz LE; Sheffer AL Expert Rev Clin Immunol; 2012 Jan; 8(1):25-32. PubMed ID: 22149337 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation. Bouillet L; Bocquet A; Belbezier A; Boccon-Gibod I Ann Allergy Asthma Immunol; 2021 Sep; 127(3):391-392. PubMed ID: 34082125 [No Abstract] [Full Text] [Related] [Next] [New Search]